KMICB - Management of Headaches and Migraines in Adults

Kent & Medway Guidance

K&M Rimegepant Prescribing Guideline for Primary Care, June 2024

K&M Management of Adults with Headaches and Migraines in Primary Care, Aug 2022 (review due Aug 2024)

Please note that this guidance refers to Fremanezumab NICE TA 631, which has since been updated to NICE TA 764. The guidance has not yet been updated following this NICE TA update.

SERMOG-08 Anti-CGRP and Botulinum Toxin Type A Migraine Prevention Pathway